Sartorius | SRT3 - Gross Profit On Sales

Stock Price
240.30
Daily Change
2.40 1.01%
Monthly
-4.00%
Yearly
-0.25%
Q1 Forecast
230.71

Sartorius reported EUR393.2M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Avita Medical AUD 14.95M 1.18M Jun/2025
Dianthus Therapeutics USD 396K 203K Sep/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Moderna USD 226M 583M Dec/2025
Organon & Co USD 854M 3M Dec/2025
Revvity USD 421.66M 47.06M Dec/2025
Sartorius EUR 393.2M 23M Sep/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Viatris USD 1.15B 223.6M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025